{"id":184053,"date":"2021-07-01T11:29:29","date_gmt":"2021-07-01T15:29:29","guid":{"rendered":"https:\/\/z3news.com\/w\/?p=184053"},"modified":"2021-07-23T10:43:47","modified_gmt":"2021-07-23T14:43:47","slug":"update-on-fda-compounding-catastrophe","status":"publish","type":"post","link":"https:\/\/z3news.com\/w\/update-on-fda-compounding-catastrophe\/","title":{"rendered":"Update on FDA Compounding Catastrophe"},"content":{"rendered":"

Help us build support in Congress to ensure you can access the customized medicines you rely on. Action Alert!<\/a><\/strong><\/p>\n

As part of its effort to implement the Drug Quality and Security Act of 2013, the FDA is poised to implement a bad policy that will limit the amount of medicines like bioidentical hormones such as estriol that compounding pharmacies can send out of state, even when patients have a doctor\u2019s prescription. This policy makes it harder for patients to get the medicines they need. There is a Congressional sign-on letter being circulated urging the FDA to delay the implementation of this rule\u2014we must urge our representatives in Congress to sign on to this letter. See our previous coverage of this issue below for more details.<\/p>\n

Last year, the FDA\u00a0made available<\/strong><\/a>\u00a0the final memorandum of understanding (MOU) with states regarding the interstate distribution of compounded drugs. It is largely unchanged from the last iteration of the MOU that was\u00a0released late last year<\/strong><\/a>.<\/p>\n

This rule concerns how much medicine traditional compounding pharmacies can send out-of-state. These sales are limited to 5% unless a state enters into an MOU permitting additional sales.\u00a0 In exchange, however, the state assumes some of the responsibility for overseeing pharmacies within their borders that send a certain amount of medicine to other states.<\/p>\n

Importantly, the final MOU does not address a key issue, which is that it shouldn\u2019t be limiting the interstate shipment of medicines\u00a0for which there is a doctor\u2019s prescription\u00a0at all; the\u00a0law only allows<\/strong><\/a>\u00a0the FDA to place some limitations on how many medicines a traditional pharmacy can send out-of-state without patient-specific prescriptions.<\/p>\n

Why does this distinction matter? Limiting the interstate shipment of compounded medicines pursuant to a doctor\u2019s prescription will prevent patients from getting the medicines they need. Certain pharmacies specialize in specific areas, such as bioidentical hormones. If you get your estriol from a pharmacy in Michigan, and you live in New Jersey, there\u2019s a real risk that you will no longer be able to get that medicine, even if you\u2019ve taken it for years. If that pharmacy has already sent 50% of their sales out-of-state, you\u2019d be out of luck.<\/p>\n

The same goes for any number of crucial medicines for vulnerable populations. One of the main purposes of compounded medicine is so that patients with allergies, patients who have difficulty swallowing pills, patients who require specialized formulations not available elsewhere, such as autistic children, or patients who require other modifications to the dietary ingredients and medicines available in the market can get the individualized treatments they need. An FDA-approved product may have peanut oil in it, so patients could go to a compounding pharmacy to get a peanut-free medicine. Limiting out-of-state sales for these pharmacies severely limits the options for patients who already have limited options.<\/p>\n

Remember, too, that the 50% limit will only apply in states that actually sign the MOU\u2014otherwise the 5% limit applies. Early indications<\/strong><\/a> are that many states will not sign the MOU.<\/p>\n

As we\u2019ve said all along, it is our opinion that the objective in all of this is to shut down compounding because it threatens Big Pharma profits, and Big Pharma funds the FDA. We have to fight back and ensure that patients can get the medicines they need.<\/p>\n

Action Alert!<\/strong> Write to your representatives in Congress and urge them to sign on to the letter from Reps. Cuellar and Dunn asking the FDA to delay implementation of its compounding MOU. Please send your message immediately.<\/strong><\/p>\n

\n
\"\"<\/a><\/figure>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Help us build support in Congress to ensure you can access the customized medicines you rely on. Action Alert!
\nAs part of its effort to implement the Drug Quality and Security Act of 2013, the FDA is poised to implement a bad policy that will limit the amount of medicines like bioidentical hormones such as estriol that compounding pharmacies can send out of state, even when patients have a doctor\u2019s prescription. This policy makes it harder for patients to get the medicines they need. There is a Congressional sign-on letter being circulated urging the FDA to delay the implementation of this rule\u2014we must urge our representatives in Congress to sign on to this letter. See our previous coverage of this issue below for more details.
\nLast year, the FDA\u00a0made available\u00a0the final memorandum of understanding (MOU) with states regarding the interstate distribution of compounded drugs. It is largely unchanged from the last iteration of the MOU that was\u00a0released late last year.
\nThis rule concerns how much medicine traditional compounding pharmacies can send out-of-state. These sales are limited to 5% unless a state enters into an MOU permitting additional sales.\u00a0 In exchange, however, the state assumes some of the responsibility for overseeing pharmacies within their borders that send a certain amount of medicine to other states.
\nImportantly, the final MOU does not address a key issue, which is that it shouldn\u2019t be limiting the interstate shipment of medicines\u00a0for which there is a doctor\u2019s prescription\u00a0at all; the\u00a0law only allows\u00a0the FDA to place some limitations on how many medicines a traditional pharmacy can send out-of-state without patient-specific prescriptions.
\nWhy does this distinction matter? Limiting the interstate shipment of compounded medicines pursuant to a doctor\u2019s prescription will prevent patients from getting the medicines they need. Certain pharmacies specialize in specific areas, such as bioidentical hormones. If you get your estriol from a pharmacy in Michigan, and you live in New Jersey, there\u2019s a real risk that you will no longer be able to get that medicine, even if you\u2019ve taken it for years. If that pharmacy has already sent 50% of their sales out-of-state, you\u2019d be out of luck.
\nThe same goes for any number of crucial medicines for vulnerable populations. One of the main purposes of compounded medicine is so that patients with allergies, patients who have difficulty swallowing pills, patients who require specialized formulations not available elsewhere, such as autistic children, or patients who require other modifications to the dietary ingredients and medicines available in the market can get the individualized treatments they need. An FDA-approved product may have peanut oil in it, so patients could go to a compounding pharmacy to get a peanut-free medicine. Limiting out-of-state sales for these pharmacies severely limits the options for patients who already have limited options.
\nRemember, too, that the 50% limit will only apply in states that actually sign the MOU\u2014otherwise the 5% limit applies. Early indications are that many states will not sign the MOU.
\nAs we\u2019ve said all along, it is our opinion that the objective in all of this is to shut down compounding because it threatens Big Pharma profits, and Big Pharma funds the FDA. We have to fight back and ensure that patients can get the medicines they need.
\nAction Alert! Write to your representatives in Congress and urge them to sign on to the letter from Reps. Cuellar and Dunn asking the FDA to delay implementation of its compounding MOU. Please send your message immediately.<\/p>\n

Share This Post<\/p>\n","protected":false},"author":773,"featured_media":184034,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"sfsi_plus_gutenberg_text_before_share":"","sfsi_plus_gutenberg_show_text_before_share":"","sfsi_plus_gutenberg_icon_type":"","sfsi_plus_gutenberg_icon_alignemt":"","sfsi_plus_gutenburg_max_per_row":"","_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":"","_ppma_block_editor_authors":""},"categories":[359],"tags":[],"ppma_author":[1001],"class_list":["post-184053","post","type-post","status-publish","format-standard","has-post-thumbnail","category-fda","entry"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t